Rubius Therapeutics poaches Novartis’ Spencer Fisk

Novartis’ former vice president and global head of cell and gene technical development and manufacturing Spencer Fisk has decided to join Rubius Therapeutics.

He takes up its senior vice president of manufacturing role as the company is looking to expand its manufacturing and development organisations.

Torben Straight Nissen, president of Rubius Therapeutics, said: “Spencer’s expertise and decades of experience in process development and manufacturing will be invaluable and I look forward to working closely together as we continue to deliver on the promise of the next generation of cellular therapies for patients in need.”

Prior to his new role, Fisk spent the last six years at Novartis where he led the CMC development-manufacturing organisation to deliver the CAR-T portfolio of the company.

He has also held a series of leadership positions for both Merck and Schering Plough.

Fish said: “Rubius is developing an entirely new class of ready-to-use cell therapeutics to treat cancer, autoimmune disorders and rare diseases.

“I look forward to leveraging the expertise i've gained while working with larger pharmaceutical companies to help Rubius take its extraordinary RTC pipeline into the clinic.”